Randomized controlled trialHumanClinical Trial, Phase III

0.1% RGN-259 (Thymosin ß4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial

International journal of molecular sciences, 2022 Dec 29. Sosne G, Kleinman HK, Springs C and 3 others.

Study type

Randomized controlled trial · Clinical Trial, Phase III

Subjects

Human participants (PubMed MeSH: Humans)

Journal

International journal of molecular sciences

Published

2022 Dec 29

PubMed

PMID 36613994 ↗

DOI

10.3390/ijms24010554 ↗

Full text

Free on PubMed Central (PMC9820614) ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Thymosin β-4 →

Indexed under

MeSH terms assigned by the National Library of Medicine.

HumansCorneaOphthalmic SolutionsThymosinTreatment OutcomeKeratitisTrigeminal Nerve DiseasesCorneal Dystrophies, HereditaryDouble-Blind Method

Other papers on Thymosin β-4

Journal article · 2012

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Journal article · 2004

Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair

Journal article · 2002

Thymosin beta 4 promotes corneal wound healing and decreases inflammation in vivo following alkali injury

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page